Keay Nakae
Stock Analyst at Chardan Capital
(4.29)
# 395
Out of 5,131 analysts
257
Total ratings
41.11%
Success rate
23.27%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $475 → $425 | $314.40 | +35.18% | 15 | Feb 13, 2026 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $2.22 | +125.23% | 6 | Feb 12, 2026 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $55.46 | +80.31% | 7 | Jan 29, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $7 → $15 | $11.17 | +34.29% | 5 | Jan 29, 2026 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.70 | +197.87% | 23 | Jan 8, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 → $80 | $63.82 | +25.35% | 23 | Jan 7, 2026 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Buy | $2 | $0.26 | +667.46% | 1 | Jan 5, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $35 | $31.91 | +9.68% | 1 | Jan 5, 2026 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $30 | $16.89 | +77.62% | 1 | Jan 5, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 | $3.85 | +211.69% | 19 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 | $15.54 | +144.53% | 14 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2.5 | $1.12 | +123.21% | 7 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $3.98 | +25.63% | 14 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $3.81 | +424.93% | 13 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 | $72.87 | -1.19% | 21 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.46 | +173.97% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $4.45 | +686.52% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $8.47 | -29.16% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.81 | +231.49% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.51 | +1,474.18% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $16.67 | -64.01% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $6.13 | +6,099.02% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $10.83 | +407.85% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $4.08 | +145.10% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $32.11 | +172.50% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.41 | +821.99% | 3 | Feb 9, 2021 |
Alnylam Pharmaceuticals
Feb 13, 2026
Maintains: Buy
Price Target: $475 → $425
Current: $314.40
Upside: +35.18%
iBio, Inc.
Feb 12, 2026
Maintains: Buy
Price Target: $5
Current: $2.22
Upside: +125.23%
Monopar Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $100
Current: $55.46
Upside: +80.31%
Korro Bio
Jan 29, 2026
Upgrades: Buy
Price Target: $7 → $15
Current: $11.17
Upside: +34.29%
Coya Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $14
Current: $4.70
Upside: +197.87%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $63.82
Upside: +25.35%
Reviva Pharmaceuticals Holdings
Jan 5, 2026
Maintains: Buy
Price Target: $2
Current: $0.26
Upside: +667.46%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $24 → $35
Current: $31.91
Upside: +9.68%
Alto Neuroscience
Jan 5, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $16.89
Upside: +77.62%
SAB Biotherapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $12
Current: $3.85
Upside: +211.69%
Dec 9, 2025
Maintains: Buy
Price Target: $38
Current: $15.54
Upside: +144.53%
Nov 20, 2025
Maintains: Neutral
Price Target: $2.5
Current: $1.12
Upside: +123.21%
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $3.98
Upside: +25.63%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $3.81
Upside: +424.93%
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $72.87
Upside: -1.19%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $1.46
Upside: +173.97%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $4.45
Upside: +686.52%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $8.47
Upside: -29.16%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $1.81
Upside: +231.49%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.51
Upside: +1,474.18%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $16.67
Upside: -64.01%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $6.13
Upside: +6,099.02%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $10.83
Upside: +407.85%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $4.08
Upside: +145.10%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $32.11
Upside: +172.50%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.41
Upside: +821.99%